<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133536</url>
  </required_header>
  <id_info>
    <org_study_id>04-077</org_study_id>
    <nct_id>NCT00133536</nct_id>
  </id_info>
  <brief_title>A/H5N1 Vaccine in Healthy Children Aged 2-9 Years</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purposes of this study are: to make sure that there are no serious side effects of an&#xD;
      experimental inactivated influenza A/H5N1 vaccine in children; and to see how the body's&#xD;
      immune system reacts to the vaccine. To look at the side effects, researchers will follow&#xD;
      children closely after vaccination. To look at immune system responses, researchers will test&#xD;
      the children's blood before and a number of times after vaccination. Participants will&#xD;
      include up to 130 healthy children ages 2-9 years. Participants will be assigned to receive&#xD;
      2, up to 3 doses of vaccine, or placebo (inactive substance). Subjects will receive at least&#xD;
      2 doses of vaccine approximately 28 days apart. If data shows an enhanced immune response&#xD;
      from a third vaccination, children will be offered a third dose of the vaccine. Participants&#xD;
      will be involved in study related procedures for up to 13 months, including up to 6 study&#xD;
      visits, plus a number of telephone calls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to assess the safety, reactogenicity, and immunogenicity of&#xD;
      45-microgram dosage level of monovalent subvirion influenza A/H5N1 virus vaccine administered&#xD;
      by intramuscular (IM) route to healthy children. The primary goal of this study is to&#xD;
      determine if this dosage level of H5N1 will result in an acceptable proportion of children&#xD;
      achieving a potentially protective post vaccination antibody titer (provisionally assigned as&#xD;
      a serum neutralizing titer of 1:40, based on studies conducted in Hong Kong during the 1997&#xD;
      H5N1 outbreak). Approximately 130 healthy children, aged 2 through 9 years, will be enrolled&#xD;
      in this multicenter, randomized, double-blinded, placebo-controlled, clinical trial to&#xD;
      receive at least 2 and up to 3 doses of an inactivated influenza A/H5N1 vaccine at a&#xD;
      45-microgram dose. One hundred subjects will be enrolled and randomly assigned into the&#xD;
      influenza A/H5N1 vaccine dose group and 20 subjects into the placebo group (in 5:1 ratio).&#xD;
      Subjects will be stratified into 2 age groups (2 to 5 years old and 6 to 9 years old).&#xD;
      Vaccine or placebo will be administered into the deltoid. Subjects randomized to receive&#xD;
      vaccine will receive 2 doses of the vaccine approximately 28 days apart. At approximately&#xD;
      month 5, subjects' parent(s) or guardian(s) will be called to remind them of the 6-month&#xD;
      follow-up visit. At the 6-month visit, subjects will be assessed for serious adverse events&#xD;
      (SAEs) and the randomization assignment, ie, to vaccine or placebo, will be unmasked to the&#xD;
      subject and parent(s) or guardian(s). Should data evaluating a third dose of the influenza&#xD;
      A/H5N1 vaccine in adults show enhanced immunogenicity, parents or guardians of subjects who&#xD;
      received vaccine will be offered a third dose, with an additional blood draw immediately&#xD;
      prior to the third dose and 28 days and 6 months thereafter. The 6-month post-Dose 3 blood&#xD;
      draw is optional. For subjects assigned to placebo, the parents or guardians will be offered&#xD;
      the opportunity to enroll the subject into a separate open-label protocol if the 2 dose&#xD;
      regimen administered to the vaccine recipients is found to be safe and immunogenic. The&#xD;
      primary endpoints of the study include: adverse event (AE) and SAE information (solicited&#xD;
      in-clinic and via memory aids, concomitant medications, and periodic targeted physical&#xD;
      assessments, as indicated); proportion of subjects achieving a serum neutralizing antibody&#xD;
      titer of 1:40 against the influenza A/H5N1 virus 28 days after receipt of second dose of&#xD;
      vaccine (approximately Day 56); and geometric mean titer (GMT) and the frequency of 4-fold or&#xD;
      greater increases in hemagglutination inhibition and neutralizing antibody titers 28 days&#xD;
      after receipt of second dose of vaccine (approximately Day 56). The secondary endpoints of&#xD;
      the study include: proportion of subjects achieving a serum neutralizing antibody titer of&#xD;
      1:40 against the influenza A/H5N1 virus 1 and 6 months after receipt of first and third doses&#xD;
      (if third dose will be administered [see study design]) of vaccine; GMT and the frequency of&#xD;
      4-fold or greater increases in serum hemagglutination inhibition antibody titer 1 and 6&#xD;
      months after receipt of first and third (if third dose will be administered [see study&#xD;
      design]) doses of vaccine; and development of serum antibody responses against antigenically&#xD;
      drifted variants of influenza H5N1 virus. This study is linked to protocol 06-0072.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event (AE) and serious adverse event (SAE) information (solicited in clinic and via memory aids, concomitant medications, and periodic targeted physical assessments.)</measure>
    <time_frame>Solicited AEs-reactogenicity following each vaccination. Unsolicited AEs-SAEs occurring during the length of the study, and nonserious events occurring 28 days after receipt of the 2nd (from enrollment) or 3rd dose of vaccine.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus.</measure>
    <time_frame>28 days after receipt of the 2nd dose of vaccine (Day 56).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer and the frequency of 4-fold or greater increases in hemagglutination inhibition and neutralizing antibody titers.</measure>
    <time_frame>28 days after receipt of the 2nd dose of vaccine (Day 56).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus.</measure>
    <time_frame>1 and 6 months after receipt of first and third doses (if third dose will be administered [see study design]) of vaccine.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer and the frequency of 4-fold or greater increases in serum hemagglutination inhibition antibody titer.</measure>
    <time_frame>1 and 6 months after receipt of first and third (if third dose will be administered [see study design]) doses of vaccine.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of serum antibody responses against antigenically drifted variants of influenza H5N1 virus.</measure>
    <time_frame>Blood samples for serum assays will be collected at day 0, approximately 1 month after each immunization, and approximately 6 months after the first immunization and third immunization (if provided).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects 45 mcg of influenza A/H5N1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects saline placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A/H5N1 Vaccine</intervention_name>
    <description>Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administered intramuscularly.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must be male or female, aged 2 through 9 years at enrollment.&#xD;
&#xD;
          -  The subject must be in good health (and not on any chronic medications), as determined&#xD;
             by medical history and a history-directed targeted physical examination.&#xD;
&#xD;
          -  Parents or guardians must be able to understand and comply with planned study&#xD;
             procedures and be available for all study visits.&#xD;
&#xD;
          -  Parents or guardians must provide written consent prior to initiation of any study&#xD;
             procedures, and subject may provide written assent as appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject must not have a known allergy to eggs or other components of the vaccine&#xD;
             or sensitivity or allergy to latex.&#xD;
&#xD;
          -  The subject must not have a history of asthma or recurrent wheezing.&#xD;
&#xD;
          -  The subject must not be undergoing immunosuppression as a result of an underlying&#xD;
             illness or treatment.&#xD;
&#xD;
          -  The subject must not have an active neoplastic disease or a history of any hematologic&#xD;
             malignancy.&#xD;
&#xD;
          -  The subject must not be using oral or parenteral steroids, inhaled steroids, or other&#xD;
             immunosuppressive or cytotoxic drugs. Note: Subjects on nasal or topical steroids will&#xD;
             be allowed to enroll in this study.&#xD;
&#xD;
          -  The subject must not have a history of receiving immunoglobulin or other blood product&#xD;
             within the 3 months prior to enrollment in this study.&#xD;
&#xD;
          -  The subject must not have received any other licensed vaccines within 2 weeks (for&#xD;
             inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this&#xD;
             study.&#xD;
&#xD;
          -  The subject must not have an acute or chronic medical condition that, in the opinion&#xD;
             of the investigator, would render vaccination unsafe or would interfere with the&#xD;
             evaluation of responses (these conditions include, but are not limited to, known&#xD;
             chronic liver disease, significant renal disease, unstable or progressive neurological&#xD;
             disorders, diabetes mellitus, and transplant recipients).&#xD;
&#xD;
          -  The subject must not have a history of severe reactions following immunization with&#xD;
             contemporary influenza virus vaccines.&#xD;
&#xD;
          -  The subject must not have an acute illness, including an axillary temperature greater&#xD;
             than 100 degrees F, within 3 days prior to vaccination.&#xD;
&#xD;
          -  The subject must not have received an experimental vaccine or medication within one&#xD;
             month prior to enrollment in this study, or expect to receive an experimental vaccine,&#xD;
             medication, or blood product during the 13-month study period.&#xD;
&#xD;
          -  The subject must not have any condition that would, in the opinion of the&#xD;
             investigator, place them at an unacceptable risk of injury or render the subject&#xD;
             unable to meet the requirements of the protocol.&#xD;
&#xD;
          -  History of Guillain-Barr√© syndrome.&#xD;
&#xD;
          -  The subject must not be participating concurrently in another clinical trial (either&#xD;
             in active phase or in follow-up phase).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Center For Vaccine Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Johnson</name_title>
    <organization>HHS/NIAID/DMID</organization>
  </responsible_party>
  <keyword>H5N1, Influenza, children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

